Sumitomo Pharma reported double-digit revenue growth in Q1FY25, driven by North America. Operating loss narrowed. Net profit stood at ¥16B in Q1FY25. The company is expected to revise FY25 guidance.
What is covered in the Full Insight:
Introduction
Q1FY25 Financial Performance
Key Products Overview
Cost Management and Structural Reforms
Future Outlook and Catalysts
Boomeranged on Thu, 3 Oct 2024 16:45
Sumitomo Pharma shares gained 37% in just two months. Book partial profit and hold core position. Valuation is still cheap and outlook is still positive. H1FY25 result announcement is on October 30.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.